Osteoprotegerin (OPG) und Receptor Activator for Nuclear Factor kappaB Ligand (RANKL) als Risikofaktoren für Entstehung und Schweregrad einer Koronaren Herzerkrankung – ein Review
- 2 September 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Wiener Medizinische Wochenschrift
- Vol. 161 (23-24), 565-570
- https://doi.org/10.1007/s10354-011-0022-7
Abstract
Osteoprotegerin (OPG), Receptor activator of nuclear factor kappaB (RANK) und dessen Ligand (RANKL) werden nicht nur als Schlüsselregulatoren des Knochenstoffwechsels beschrieben, sondern auch als wichtige Regulatoren immunologischer Funktionen erkannt. Eine koronare Herzerkrankung (KHK) entwickelt sich über Jahre und ist sehr oft die Folge entzündlicher Prozesse, die eine Schädigung des Endothels verursachen. Die rezente Literatur beschreibt OPG bei Patienten mit einer KHK als wichtigen Prädiktor von Mortalität und Morbidität. Initially described as key regulators in metabolic bone disease osteoprotegerin (OPG), receptor activator of nuclear factor kappa B (RANK) and RANK ligand (RANKL) have also been discriminated as regulators in immunologic function. Cardiovascular diseases (CVD) develop over many years in life and are often triggered by inflammatory processes within the vessel wall that lead to vascular remodeling. Recently some study groups have described OPG as a prognostic parameter for mortality and morbidity in cardiovascular patients.Keywords
This publication has 78 references indexed in Scilit:
- Osteoprotegerin Predicts Progression of Chronic Heart Failure: Results From CORONACirculation: Heart Failure, 2011
- Biomarkers of the Osteoprotegerin PathwayArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?Wiener Medizinische Wochenschrift, 2010
- Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failureEuropean Journal of Heart Failure, 2008
- Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in
ldlr
(−/−)
MiceCirculation, 2008
- Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritisAtherosclerosis, 2007
- Enhanced T-Cell Expression of RANK Ligand in Acute Coronary SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Prognostic value of osteoprotegerin in heart failure after acute myocardial infarctionJournal of the American College of Cardiology, 2004
- An Integrated Physical Map of 8q22–q24: Use in Positional Cloning and Deletion Analysis of Langer–Giedion SyndromeGenomics, 2001
- Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory FactorPublished by Elsevier BV ,1998